More from the Company Monthly Newsletter December 2018
Happy New Year!
During December we signed a distributor agreement with AMI Technologies in Israel and concluded the rights issue with preferential rights for the company's shareholders.
We signed a distributor agreement with AMI Technologies LTD., which is a leading distributor of medical devices in Israel. The company was founded 1986, and has been working with medical devices for more than 30 years. The AMI Technologies portfolio includes products in intensive care & anesthesia, cardiac and valvular surgery, neuroimaging and interventionskardiologi. They represent a number of well-known international brands, including BARD and Stryker, in the local market.
The subscription period in Quickcool’s rights issue with preferential rights for the company's shareholders ended just before the holidays. The issue was subscribed to 67 per cent. The subscription amounts to SEK 4.3 million (of which SEK 2.2 million is added by offsetting), before deducting the issue costs, which are estimated at approximately SEK 0.3 million. We appreciate your continuous support and confidence.
It is not easy to summarise the past year in a few sentences. It was an active and eventful year. Supplier and component issues caused delay in launching the QuickCool® SYSTEM. There are some activities that are worth mentioning. During the year we have, among other things, further strengthened our patent portfolio, recertified our QMS in accordance with ISO 13485:2016, entered a financing agreement with EHGO, placed orders for the 0-series, and signed distributor agreements in the UK, Ireland, Portugal, Spain, Estonia, Latvia, Lithuania, and Israel.
We look forward to launching the QuickCool® SYSTEM during 2019.
The potential for QuickCool® SYSTEM is confirmed by the interest shown by distributors. Noteworthy and worth repeating is the potential for the global Targeted Temperature Management (TTM) market that was estimated at approximately USD 2.4 billion in 2017, but is expected to increase to USD 2.72 billion in 2022 and USD 4.6 billion in 2025. To access the full report, clink on the following link:
http://www.introduce.se/foretag/quickcool/Equity-research/2018/10/quickcool---to-build-a-commercial-organization/
Follow us on LinkedIn. Additional information about QuickCool and our solution may be found on our homepage: http://www.quickcool.se/en/home.html
Wishing you a happy new year with kind regards,
Fredrik
Fredrik Radencrantz
CEO
QuickCool AB
Ideon Science Park
Beta 6, Scheelevägen 17 - SE-223 70 Lund - Sweden
E-mail: fredrik.radencrantz@quickcool.se Web: www.quickcool.se
Mobile +46 (0)73 834 1188
Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se
Tags: